

Accelerated Type 1 diabetes detection that meets you where you are


Identify more patients that may have early-stage Type 1 diabetes (T1D)—with no changes to your existing workflows or resources. Reveal for T1D’s advanced clinical AI solution is simple to deploy and uses existing EHR data to accelerate the diagnosis and treatment of Type 1 diabetes, resulting in higher clinical and financial yield.

Lucem Health is inviting leading health systems to join a **fully-sponsored** Type 1 diabetes early detection program—shape the future of Type 1 diabetes care while improving outcomes, today.



Proactive care powered by precision identification


Reveal for T1D helps healthcare provider organizations proactively find patients that may have presymptomatic, early-stage (stage 1 and 2) Type 1 diabetes.




Identify: AI analyzes existing patient data to surface those who may benefit from T1D antibody testing based on clinical patterns.



Engage: Provide patient education on the importance of early diagnosis for T1D and guidance toward confirmatory testing.



Accelerate: Support the efficient implementation of care pathways from early identification to clinical evaluation and intervention.



Impact: Support patients in receiving earlier intervention, which may help prevent life-threatening complications and improve long-term health.

How the Reveal for T1D Early Adopter Program works

Zero cost. Full support. Real results.

- Gain full access to Reveal for T1D for one year with no software or implementation fees.
- Get set up quickly with hands-on support from our implementation and customer success teams.
- Assign a clinical lead to oversee evaluation of identified patients for screening, working closely with us to ensure success.

How to find out more

Reach out to Lucem Health at DetectT1D@lucemhealth.com to discuss the opportunity and any logistical considerations specific to your health system.

Why Type 1 diabetes?

Diagnostic Opportunity

85-90% of individuals with Type 1 diabetes are **diagnosed at its latest stage** (stage 3), resulting in increased morbidity and mortality.¹

Diagnostic Impact

Early intervention reduces acute complications, **improves long-term clinical outcomes**, and supports access to therapies that may delay progression to Stage 3 diabetes.

Financial Opportunity

Reduce acute care utilization to **improve value-based care metrics and generate new service line revenue** from earlier intervention.